Sandbox reserved CDK2 Oxindole Inhibitor
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
== Cyclin-Dependend Kinase 2 (CDK2) in Complex with an Oxindole Inhibitor == | == Cyclin-Dependend Kinase 2 (CDK2) in Complex with an Oxindole Inhibitor == | ||
<StructureSection load='1fvt' size='350' side='left' caption='Structure of CDK2 with 4-(5-bromo-2-oxo-2h-indol-3-ylazo)-benzenesulfonamide (PDB entry [[1fvt]])' scene=''> | <StructureSection load='1fvt' size='350' side='left' caption='Structure of CDK2 with 4-(5-bromo-2-oxo-2h-indol-3-ylazo)-benzenesulfonamide (PDB entry [[1fvt]])' scene=''> | ||
| - | *The representation displayed is that of cyclin-dependent kinase 2 (CDK2) | + | *The representation displayed is that of cyclin-dependent kinase 2 (CDK2) interacting with an oxindole inhibitor. The ligand pictured is the <scene name='Sandbox_reserved_CDK2_Oxindole_Inhibitor/Oxindole_inhibitor/2'>oxindole inhibitor</scene>, 4-(5-bromo-2-oxo-2h-indol-3-ylazo)- benzenesulfonamide. <scene name='Sandbox_reserved_CDK2_Oxindole_Inhibitor/Cdk2/1'>CDK2</scene> is part of the Ser/Thr protein kinases. CDK2 is a positive regulator of the eukaryotic cell cycle progression and is a catalytic unit that helps the cell progress from the G1 phase to the S phase. |
*In the study “The Structure of Cyclin-Dependent Kinase 2 (CDK2) in Complex with an Oxindole Inhibitor,” researchers studied whether using a topical oxindole inhibitor would reduce the chemotherapy-induced alopecia (CIA). Alopecia is characterized by hair loss. By inhibiting the CDK2, the cell cycle is slowed and the sensitivity to the epithelium from many cell cycle-active antitumor agents is reduced. Thus, a reduction in hair loss can be possible. | *In the study “The Structure of Cyclin-Dependent Kinase 2 (CDK2) in Complex with an Oxindole Inhibitor,” researchers studied whether using a topical oxindole inhibitor would reduce the chemotherapy-induced alopecia (CIA). Alopecia is characterized by hair loss. By inhibiting the CDK2, the cell cycle is slowed and the sensitivity to the epithelium from many cell cycle-active antitumor agents is reduced. Thus, a reduction in hair loss can be possible. | ||
*The oxindole inhibitor interacts with the CDK2 through a small <scene name='Sandbox_reserved_CDK2_Oxindole_Inhibitor/Binding_pocket/1'>binding pocket</scene>. | *The oxindole inhibitor interacts with the CDK2 through a small <scene name='Sandbox_reserved_CDK2_Oxindole_Inhibitor/Binding_pocket/1'>binding pocket</scene>. | ||
Revision as of 19:51, 25 September 2012
Cyclin-Dependend Kinase 2 (CDK2) in Complex with an Oxindole Inhibitor
| |||||||||||
